Cooperative activity of cytotoxic chemotherapy with antiangiogenic thrombospondin-I peptides, ABT-526 in pet dogs with relapsed lymphoma

Clinical Cancer Research

Volumn 12, Issue 24, 2006, Pages 7456-7464

  Rusk, Anthony ^a,f   Cozzi, Elizabeth ^b   Stebbins, Marty ^a   Vail, David ^c   Graham, Joanne ^d   Valli, Victor ^e   Henkin, Jack ^b   Sharpee, Rick ^b   Khanna, Chand ^a  

^a Animal Cancer Investigation LLC   (United States)

^b ABBOTT LABORATORIES   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

^d Arboretum View Animal Hospital   (United States)

^e UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^f Friendship Hospital for Animals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABT 256; ALANINE AMINOTRANSFERASE; ANGIOGENESIS INHIBITOR; LOMUSTINE; PLACEBO; THROMBOSPONDIN 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CONJUNCTIVITIS; CONTROLLED STUDY; CYTOTOXICITY; DOG; DRUG ACTIVITY; GASTROENTERITIS; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT RESPONSE; UVEITIS;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE PROGRESSION; DOG DISEASES; DOGS; DOUBLE-BLIND METHOD; FEMALE; LOMUSTINE; LYMPHOMA, NON-HODGKIN; MALE; NEOPLASM RECURRENCE, LOCAL; PEPTIDE FRAGMENTS; PLACEBOS; SURVIVAL ANALYSIS; THROMBOSPONDIN 1; TIME FACTORS;

EID: 33846221453     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-0110     Document Type: Article

References (30)

1. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307:58-62.
2. Purow B, Fine HA. Progress report on the potential of angiogenesis inhibitors for neuro-oncology. Cancer Invest 2004;22:577-87.
3. Folkman J. Endogenous angiogenesis inhibitors. APMIS 2004;112:496-507.
4. Folkman J. Angiogenesis inhibitors: a new class of drugs. Cancer Biol Ther 2003;2:S127-33.
5. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 2005;438:967-74.
6. Griffioen AW, Molema G. Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol Rev 2000;52:237-68.
7. Simantov R, Febbraio M, Silverstein RL, The antiangiogenic effect of thrombospondin-2 is mediated by CD36 and modulated by histidine-rich glycoprotein. Matrix Biol 2005;24:27-34.
8. Dameron KM, Volpert OV, Tainsky MA, Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 1994;265:1582-4.
9. Haviv F, Bradley MF, Kalvin DM, et al. Thrombospondin-1 mimetic peptide inhibitors of angiogenesis and tumor growth: design, synthesis, and optimization of pharmacokinetics and biological activities. J Med Chem 2005;48:2838-46.
10. Hoekstra R, de Vos FY, Eskens FA, et al. Phase I safety, pharmacokinetic, and pharmacodynamic study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced cancer. J Clin Oncol 2005;23:5188-97.
11. Volpert OV, Zaichuk T, Zhou W, et al. Inducer-stimulated Fas targets activated endothelium for destruction by anti-angiogenic thrombospondin-1 and pigment epithelium-derived factor. Nat Med 2002;8:349-57.
12. Westphal JR. Technology evaluation: ABT-510, Abbott. Curr Opin Mol Ther 2004;6:451-7.
13. Khanna C, Lund EM, Redic KA, et al. Randomized controlled trial of doxorubicin versus dactinomycin in a multiagent protocol for treatment of dogs with malignant lymphoma. J Am Vet Med Assoc 1998;213: 985-90.
14. Lucroy MD, Phillips BS, Kraegel SA, Simonson ER, Madewell BR. Evaluation of single-agent mitoxantrone as chemotherapy for relapsing canine lymphoma. J Vet Intern Med 1998;12:325-9.
15. McDonald DM, Munn L, Jain RK. Vasculogenic mimicry: how convincing, how novel, and how significant? Am J Pathol 2000;156:383-8.
16. Teske E, van Heerde P, Rutteman GR, Kurzman ID, Moore PF, MacEwen EG. Prognostic factors for treatment of malignant lymphoma in dogs. J Am Vet Med Assoc 1994;205:1722-8.
17. Tsuchida Y, Therasse P. Response evaluation criteria in solid tumors (RECIST): new guidelines. Med Pediatr Oncol 2001;37:1-3.
18. O'Reilly MS. Therapeutic strategies using inhibitors of angiogenesis. Methods Mol Biol 2003;223: 599-634.
19. Bibby MC. Orthotopic models of cancer for preclinical drug evaluation: advantages and disadvantages. Eur J Cancer 2004;40:852-7.
20. Hansen K, Khanna C. Spontaneous and genetically engineered animal models: use in preclinical cancer drug development. Eur J Cancer 2004;40: 858-80.
21. Khanna C, Hunter K. Modeling metastasis in vivo. Carcinogenesis 2005;26:513-23.
22. Eiben GL, Velders MP, Schreiber H, et al. Establishment of an HLA-A*0201 human papillomavirus type 16 tumor model to determine the efficacy of vaccination strategies in HLA-A*0201 transgenic mice. Cancer Res 2002;62:5792-9.
23. London CA, Hannah AL, Zadovoskaya R, et al. Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies. Clin Cancer Res 2003;9:2755-68.
24. Bronchud MH. Principles of molecular oncology. 2nd ed. Totowa (NJ): Humana Press; 2004. p. xxi, 709.
25. Thomas R, Fiegler H, Ostrander EA, Galibert F, Carter NP, Breen M. A canine cancer-gene microarray for CGH analysis of tumors. Cytogenet Genome Res 2003;102:254-60.
26. Mellanby RJ, Herrtage ME, Dobson JM. Treatment of canine lymphoma by veterinarians in first opinion practice in England. J Small Anim Pract 2002;43: 198-202.
27. Ettinger SN. Principles of treatment for canine lymphoma. Clin Tech Small Anim Pract 2003;18:92-7.
28. Moore AS, Ogilvie GK, Ruslander D, et al. Evaluation of mitoxantrone for the treatment of lymphoma in dogs. J Am Vet Med Assoc 1994;204:1903-5.
29. Moore AS, London CA, Wood CA, et al. Lomustine (CCNU) for the treatment of resistant lymphoma in dogs. J Vet Intern Med 1999;13:395-8.
30. Keller ET, MacEwen EG, Rosenthal RC, et al. Evaluation of prognostic factors and sequential combination chemotherapy with doxorubicin for canine lymphoma. J Vet Intern Med 1993;7:289-95.